New insider activity at CVS Health ( (CVS) ) has taken place on February 20, 2025.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Director Michael F. Mahoney made a significant investment in CVS Health by purchasing 30,000 shares of the company’s stock. The total value of this transaction amounts to $2,001,000, indicating strong confidence in the company’s future performance.
Recent Updates on CVS stock
CVS Health has seen a series of price target upgrades by analysts, reflecting a positive outlook for the company. Argus raised its target due to CVS’s strategic position to benefit from the aging U.S. population and efforts to reduce healthcare costs, alongside effective management of its Health Benefits segment. RBC Capital’s increased target is driven by CVS moving past its earnings trough and setting promising 2025 guidance, particularly in Medicare Advantage margin recovery. Deutsche Bank’s upgrade is based on a positive narrative for 2025. These adjustments come amid CVS’s mixed earnings report, which highlighted revenue growth and leadership in the biosimilar market, but also challenges in Medicare Advantage and pharmacy operating income. The company’s strategic focus on transparent pricing models and cost efficiency is seen as critical to overcoming these challenges.
More about CVS Health
YTD Price Performance: 47.91%
Average Trading Volume: 13,556,499
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $82.67B